Pfizer Inc. (PFE)
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
Pfizer: The AI Hedge That Pays You To Stay Defensive
Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.
Pfizer: The Post-Pandemic Turnaround Is Already Underway
Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait
McDonald's (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now?
‘It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend
Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.
